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Abstract: The introduction of the atypical antipsychotic drugs represents an important advance 
in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety 
profiles of these agents seem to be superior to that of the classical neuroleptics. As would be 
predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an 
atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about 
additional improvement in the social functioning and quality of life of patients with schizophrenia. 
Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression 
scores. The major concern regarding the safety of the atypical antipsychotics is related to their 
propensity to induce weight gain and alter glucose and lipid metabolism. Amisulpride has one of 
the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly 
lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than 
conventional antipsychotics. Amisulpride is well tolerated with regard to anxiety and insomnia, 
and not notably different from placebo. Amisulpride has a pronounced prolactin-elevating effect 
which appears to be independent of dosage and duration of administration. Hyperprolactinemia 
rapidly reverses following amisulpride discontinuation. Amisulpride benefits patients with 
negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with 
predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/
long-term treatment, as demonstrated in studies of up to 12 months. In terms of relevance of the 
effects, superiority is observed for quality of life, social adaptation, and functioning, as measured 
by the Quality of Life and Functional Status Questionnaire scales. In conclusion, amisulpride is 
an antipsychotic agent with proven efficacy and good tolerability. Moreover, this drug can help 
people with schizophrenia to attain social reinsertion.
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Introduction
Nowadays, new treatments for schizophrenia are more ambitious, aiming to improve 
not only psychotic symptoms, but also quality of life and social reinsertion. We 
briefly but critically outline advances in the treatment of schizophrenia from the 
mid-1970s up to the present. For many years, it was widely accepted that any 
effective drugs for schizophrenia would also induce extrapyramidal side effects 
(EPS), and the term “neuroleptic” was originally used to describe such neurologic 
side effects. However, adverse effects, such as movement disorders and sedation, are 
problematic and can result in noncompliance with medication. Positive symptoms, 
such as delusions,   hallucinations, and thought disorders, are more often experienced 
in the acute phases of the illness than are negative symptoms, such as poverty of Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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speech, lack of   motivation, apathy, and inability to express 
emotions.1 However,   negative symptoms are probably the 
more disabling, and may not respond as well to typical 
antipsychotic drugs. In addition to efficacy issues, safety 
of medication also influences the choice of antipsychotic 
agent. Atypical antipsychotic drugs, by definition, differ 
from typical antipsychotic agents in producing significantly 
fewer EPS and carrying a lower risk of tardive dyskinesia in 
vulnerable clinical populations at doses that result in com-
parable control of psychosis. Effects on neuronal survival 
and plasticity, together with decreased neurotoxicity, might 
also contribute to their clinical advantages over typical 
neuroleptic drugs.2
Pharmacologic profiles of atypical 
antipsychotics
The atypical drugs differ from the typicals in their mecha-
nism of action, but not all share the same mechanism 
(Tables 1 & 2). Clozapine, the prototype of these agents, 
has been found to improve delusions and hallucinations in 
patients who fail to respond to other antipsychotic drugs, and 
to reduce the risk of   suicide. These agents have been found 
to increase cortical dopamine and acetylcholine release, 
as well as to have a variety of effects on the glutamatergic 
system not shared by the typical agents.2 The term “atypi-
cal” was then accepted as including the characteristics com-
mon to those antipsychotic drugs developed more recently, 
including absence of hyperprolactinemia, greater efficacy in 
treating positive and negative symptoms as well as symptoms 
of disorganization, and absence of tardive dyskinesia or 
dystonia after being administered chronically.3,4 At least in 
clinical circles, most would agree that clozapine, risperidone, 
olanzapine, quetiapine, sertindole, ziprasidone, aripiprazole, 
and amisulpride are atypical, even though many of those 
agreeing to the above list may disagree on the criteria of 
definition. When compared with older antipsychotic drugs, 
atypical antipsychotics show fewer EPS and require less 
concomitant anticholinergic use, even when controlling for 
the high doses of haloperidol that have been conventionally 
used in such studies.5
The second most commonly shared feature is that most 
of the newer atypical antipsychotics show either no, or only 
transient, prolactin elevation. The two notable exceptions in 
this regard are risperidone and amisulpride, and it is now 
understood that this exception may largely be attributed to 
these drugs having a higher peripheral/central distribution 
ratio, thereby leading to excessive dopamine blockade in the 
pituitary that lies outside of the blood–brain barrier.6
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Conventional antipsychotics continue to be the first choice 
when just cost of treatment is considered, which remains 
important in poor regions. It is likely that the next generation 
of treatments will have to move beyond reliance on a single 
drug as the sole treatment for the multidimensional character-
istics of schizophrenia. Most new antipsychotics introduced 
onto the market in the past two decades (eg, risperidone and 
olanzapine) have been multireceptor-acting agents, especially 
having concomitant 5-HT2 receptor antagonism.7 A notable 
exception to this has been amisulpride, a benzamide derivative 
that has high and similar affinities for the dopamine D2 and D3 
receptor subtypes and is devoid of any significant affinity to 
other receptor systems.8 Yet, amisulpride shows most of the 
attributes of atypicals, ie, a lower risk of EPS, a somewhat 
greater improvement in positive and negative symptoms, 
and better overall outcome in longer-term follow-up studies 
compared with more conventional serotonin-dopamine or 
multireceptor atypical antipsychotics.9,10
Amisulpride is a highly selective dopamine D2-like 
receptor antagonist (Ki = 2.8 nmol/L for D2 receptors and 
Ki = 3.2 nmol/L for D3 receptors), with several orders of 
magnitude higher affinity for D2/D3 receptors than any other 
receptor population.8 A positron emission tomography study 
of amisulpride-treated patients found no significant binding to 
5-HT2 A receptors.10 In clinical trials, amisulpride has shown 
therapeutic benefit, with a profile of side effects similar to 
that of placebo.9 This and its highly specific receptor profile 
make it ideally suited to test whether antipsychotic efficacy 
and a low incidence of EPS may be achieved purely by 
selective action at limbic cortical dopamine D2/D3 receptors 
in vivo.11
Some meta-analyses have identified clozapine, amisul-
pride, risperidone, and olanzapine as being significantly 
more effective than first generation (typical) antipsychotics 
and other second-generation (atypical) antipsychotics.10–12 
Clinically, amisulpride is characterized by a side effect 
profile most resembling that of an atypical antipsychotic 
due to its low EPS burden.9 However, like risperidone and 
first-generation antipsychotic drugs, amisulpride causes large 
elevations in serum prolactin levels, most likely due to its 
potent D2/D3 antagonist properties.13 Thus, despite having 
a pharmacologic profile reminiscent of a typical antipsy-
chotic in that it exhibits high D2 affinity and low 5-HT2A 
affinity, amisulpride therapeutically resembles atypical 
antipsychotics. The identification of the 5-HT7a receptor 
as a target blocked by amisulpride suggests a plausible 
explanation for its antidepressant efficacy. Changes in 
5-HT7 receptor function have been shown to result from 
chronic antidepressant treatment.14,15 The 5-HT7a receptor 
antagonism, and not D2/D3 receptor antagonism, likely under-
lies the antidepressant actions of amisulpride.16 Moreover, 
5-HT7 receptor antagonists and presently approved antide-
pressants also appear to have similar effects on hippocampal 
neurogenesis.17
Amisulpride: Safety and tolerability
Patients with schizophrenia have been found to have 
increased somatic morbidity and mortality risks relative to 
the general population.18,19 Weight gain might contribute 
to their risk of morbidity and mortality by leading to 
an increase in lipid dysregulation, hypertension, Type 2 
diabetes mellitus, cardiovascular disease, and other related 
diseases.20,21 In addition, being overweight usually leads to 
lower self-image and self-esteem, decreased quality of life, 
and social disadvantages, and is associated with medication 
noncompliance.22–24 Recently, metabolic syndrome in patients 
with schizophrenia has drawn enormous attention from 
researchers. Previous studies showed that approximately 
28.7%–60.0% of patients with schizophrenia-related dis-
orders have metabolic syndrome.25,26 Most studies show 
that the prevalence of metabolic syndrome in patients with 
schizophrenia or schizophrenia-related disorders is higher 
than that in the normal population.26,27
Choosing the right antipsychotic is one of the most 
challenging issues when treating schizophrenia. Next to 
efficacy issues, safety of medication, including subjectively 
distressing side effects (sedation, hypersalivation or dry 
mouth, akathisia, sexual dysfunction) with negative medical 
consequences (weight gain, orthostatic hypotension, 
diabetes, hyperprolactinemia, corrected QT prolongation) 
and life-threatening adverse events (agranulocytosis, neu-
roleptic malignant syndrome), also influence the choice of 
medication.28,29
“Atypical” is a term widely used to describe some 
antipsychotics with specific characteristics, such as minimal 
risk of acute and chronic movement disorders and less 
sedation.30 The atypical antipsychotic drugs are also thought 
to be more effective than conventional drugs in the treat-
ment of negative symptoms in schizophrenia, although 
this has not yet been adequately established.31 At present, 
new antipsychotics are routinely investigated for their pos-
sible effect on negative symptoms. In spite of their better 
tolerability profile, CATIE (the Clinical Antipsychotic Trials 
of Intervention Effectiveness) showed a high dropout rate 
with atypical antipsychotics because of either inefficacy or 
intolerable side effects.32 The atypical antipsychotic drugs Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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are a class of agents that have become the most widely 
used to treat a variety of psychoses because of their supe-
riority with regard to EPS. The major concern regarding 
the safety of the atypical antipsychotics is related to their 
propensity to induce weight gain and alter glucose and lipid 
metabolism. Their main clinical advantage beyond low EPS 
is their ability to improve cognition (to some extent), which 
is one of the key deficits in schizophrenia. Further study is 
needed to define their mechanism of action, particularly 
with regard to long-term effects on neuronal plasticity and 
survival. Several studies have found that amisulpride and 
risperidone are better tolerated than haloperidol with regard 
to EPS.33,34 Weight gain was also shown to be significantly 
greater with risperidone than with amisulpride (1.4 kg versus 
0.4 kg, P = 0.026).35
In a six-month treatment period, significantly fewer 
amisulpride-treated patients presented a weight increase of 7% 
or higher than that of baseline compared with those receiv-
ing risperidone (18% versus 34%).36 Additional evidence 
for decreased levels of weight gain in amisulpride-treated 
patients relative to olanzapine-treated patients comes from 
both an eight-week study (weight gain in the olanzapine 
versus the amisulpride group 2.7 + 3.9 kg versus 0.9 + 3.2 kg, 
respectively) and a six-month study (weight gain in the 
olanzapine versus the amisulpride group 3.9 kg + 5.3 versus 
1.6 + 4.9 kg, respectively).37,38 Recently, a meta-analysis of 
all randomized and double-blind studies demonstrated that 
amisulpride treatment was significantly associated with rela-
tively low weight gain.39 Collectively, these findings suggest 
that amisulpride is an atypical antipsychotic drug with a lower 
risk of weight gain. Both amisulpride and ziprasidone were pre-
ferred to olanzapine in patients who had recently experienced 
weight gain.40,41 This makes sense because second-generation 
antipsychotics do not appear to differ regarding efficacy, but 
both amisulpride and ziprasidone have been shown to cause 
less weight gain than other compounds.38,42,43
During the treatment course, the amisulpride-treated 
patients showed significantly decreased fasting triglycer-
ide, total cholesterol, glucose, and insulin resistance levels, 
decreased diastolic blood pressure and pulse rate, and a 
significant increase in high-density lipoprotein cholesterol 
levels after switching to amisulpride (all with a P , 0.05). 
The prevalence of metabolic syndrome in amisulpride-treated 
patients also decreased significantly from 65.2% to 30.4% 
(McNemar test, P , 0.0005). These findings suggest that 
switching to amisulpride could be an effective treatment of 
overweight or obese psychiatric patients treated previously 
with other second-generation antipsychotics.44
In addition to weight reduction, this study showed that 
the lipid profiles in these overweight or obese patients also 
improved significantly. A growing body of evidence indicates 
that use of some atypical antipsychotics, including clozapine 
Table 2 Relative affinities of antipsychotic drugs at some neurotransmitter receptors relevant to metabolic side effects8,32,51
Dopamine 
D2 Ki (nM)
Haloperidol  
2.0
Clozapine 
431
Olanzapine  
72
Risperidone 
4.9
Paliperidone 
9.4
Quetiapine 
567
Ziprasidone 
4.0
Aripiprazole 
0.95
Asenupine   
1.0
α1A-
adrenergic
0.17 [12] 270  
[1.6]
0.66  
[109]
0.98  
[5.0]
3.8  
[2.5]
25  
[22]
0.22  
[18]
0.038  
[25]
1.1  
[1,2]
α2A-
adrenergic
,10−2  
[.1000]
3.0  
[142]
0.24  
[314]
0.032  
[151]
2.0  
[4.7]
0.16  
[3600]
0.025  
[160]
0.012  
[74]
[1.3]
Histamine  
H1
,10−2  
[.1000]
220  
[2.0]
15  
[4.9]
0.96  
[5.2]
1.7  
[5.6]
76  
[7.5]
0.031  
[130]
0.032  
[28]
1.3  
[1.0]
Muscarinic  
M3
,10−2  
[.1000]
17  
[25]
1.4  
[51]
,10−2  
[.104]
,10−2  
[.104]
0.29  
[1943]
,10−2  
[.1000]
,10−2  
[.1000]
,10−2 
[.1000]
5-HT1A ,10−2  
[.1000]
4.1 (a)  
[105]
0.036  
[2063]
0.011  
[427]
0.015  
[640]
1.3 (a)  
[430]
0.053 (a)  
[76]
0.17* (a)  
[5.6]
0.52 (a)  
[2.5]
5-HT1B 0.012  
[165]
1.1  
[398]
0.14  
[509]
0.091  
[53.6]
0.087  
[109]
0.52 
[1109]
1.0 (a)  
[4.0]
,10−2  
[830]
0.33  
[4.0]
5-HT2A 0.035  
[57]
81  
[5.35]
30  
[3.73]
29  
[0.17]
4.9  
[1.9]
2.8  
[200]
13  
[0.30]
0.11*  
[8.7]
18  
[0.071]
5-HT2C ,10−2  
[.1000]
46  
[9.44]
12  
[10.2]
0.41  
[12]
0.20  
[48]
0.22  
[2500]
0.31  
[13]
0.043* (a)  
[22.4]
37  
[0.035]
5-HT6 ,10−2  
[.1000]
25  
[17]
12  
[6.0]
,10−2  
[.1000]
,10−2  
[.1000]
0.30  
[1864]
0.066  
[61]
,10−2  
[642]
52  
[0.25]
Notes: Values indicate drug affinity for the receptor expressed relative to dopamine D2 receptor affinity, calculated (D2 Ki ÷ receptor Ki); receptor Ki [nM] is included in 
square brackets below the relative affinity value. Affinity values approaching unity and above (shown in bold type) indicate the likelihood of substantial receptor occupancy 
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and olanzapine, may be linked to impairment in some health-
related lipid indices. For instance, in a prospective study, 
schizophrenia patients treated with olanzapine and clozapine 
for four weeks showed significantly elevated triglyceride and 
total cholesterol levels and decreased high-density lipoprotein 
cholesterol levels.45
Correlation between 
pharmacological profile  
and effects of amisulpride
Amisulpride is a unique atypical antipsychotic that selectively 
blocks D2 and D3 receptors presynaptically in the frontal 
cortex, possibly enhancing dopaminergic transmission, and 
postsynaptically in the limbic areas, possibly reducing it. 
Thus, dopaminergic overactivity in the frontal cortex and 
underactivity in the limbic areas, can be treated simultane-
ously, alleviating both positive and negative symptoms of 
schizophrenia, respectively.46 Additionally, the finding that 
amisulpride is a highly effective antidepressant via antago-
nism at 5-HT7 receptors would make its mechanism of action 
a unique one relative to other approved antidepressant drugs, 
and supports the development and/or testing of more selective 
5-HT7 receptor antagonists to treat depression in humans,16 
including their effects on negative symptoms, cognitive 
dysfunction, mood, morbidity and mortality, work and social 
function, quality of life, and family and societal burden.
Other studies have demonstrated superiority over other 
antipsychotic agents, such as the atypical risperidone, in 
terms of social interactions and performance, as well as in 
terms of relevance of the therapeutic effect observed. In addi-
tion to low levels of EPS, as with all atypicals, amisulpride 
also shows a low incidence of side effects, such as weight 
gain, that may contribute to improved compliance and 
enhanced long-term efficacy.46
Quality of life, patient satisfaction, 
acceptability, and adherence
Schizophrenia is a chronic disorder that results in signifi-
cant social, psychologic, and occupational dysfunction. Not 
surprisingly, schizophrenic patients score very poorly on 
subjective and objective measures of quality of life, even 
when compared with patients with other chronic psychiatric 
conditions, such as depression or anxiety disorders, and long-
term functional impairment is very frequent.47
Quality of life measures are especially important when 
treating patients with chronic conditions, such as schizo-
phrenia, which significantly impair their way of life. Every 
aspect of everyday life is affected, including where they live 
and work, what activities they can perform, and how they 
interact with other people. Ideally, schizophrenia treatment 
should protect against relapse, which then becomes the 
foundation for improvements in quality of life and level of 
functioning.48
The atypical antipsychotics lack many of the problems 
associated with traditional treatments, and evidence suggests 
that they may be associated with a higher subjective qual-
ity of life (Table 3).49 However, the atypical antipsychotics 
may also differ from each other on a whole range of factors. 
Amisulpride has a good safety and tolerability profile, with 
fewer EPS than the conventional antipsychotics and a low 
incidence of anticholinergic side effects. As for other antip-
sychotics, corrected QT warnings are stated on the labeling 
for some countries, even though postmarketing surveillance 
for amisulpride shows no cause for concern.50
Improvement in quality of life and social functioning, 
with consequent reintegration into society, is clearly a major 
goal of treatment for schizophrenia. The improved safety and 
tolerability profile of the atypical antipsychotics, combined 
with their benefits on negative symptoms and cognitive 
impairment, should help achieve this aim.51 The atypical 
antipsychotic, amisulpride, has an improved safety and 
tolerability profile, and has been shown to be significantly 
more effective than placebo and haloperidol on a number of 
quality of life and social functioning scales, including the 
Global Assessment of Functioning, the Quality of Life Scale, 
Table 3 Quality of life
Number 
of studies
Number of  
participants
Hedges’ g  
(95% CI)
P value
Amisulpride 1 194 −0.31  
(−0.60 to −0.03)
0.030
Aripiprazole 1 206 0.06  
(−0.22 to 0.33)
0.683
Clozapine 1 311 −0.24  
(−0.46 to −0.01)
0.039
Olanzapine 5 1450 −0.07  
(−0.23 to 0.09)
0.398
Quetiapine 2 166 0.12  
(−0.18 to 0.43)
0.432
Risperidone 4 330 −0.02  
(−0.23 to 0.20)
0.887
Sertindole 1 105 −0.44  
(−0.83 to −0.05)
0.027
Ziprasidone 1 72 0.03  
(−0.43 to 0.49)
0.905
Notes: Quality of life was reported in only 16 studies. Only amisulpride, clozapine, 
and sertindole were better than first-generation antipsychotic drugs. In three further 
olanzapine studies, no significant difference was reported for the related idea of 
patients’ attitude towards treatment (n = 171, −0.36, 95% confidence interval (CI): 
−0.90–0.21; P = 0.21. Data are Hedge’s g (95% Ci) or relative risk (95% Ci).Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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the Functional Status Questionnaire, and the Psychosocial 
Aptitude Rating Scale.50
Conclusion
In conclusion, amisulpride, in addition to its proven clinical 
efficacy, may help reintegration of the schizophrenic 
patient back into social inclusion. The negative symptoms 
of schizophrenia are characterized by poverty of speech, 
blunted affect, lack of initiative, poor motivation, and a gen-
eral slowness and underactivity, all of which result in social 
withdrawal. This may reflect the fact that new-generation 
antipsychotics have more distinct differences in their safety 
and tolerability profiles than in their efficacy characteristics. 
Although this knowledge helps to guide clinicians in drug 
choice, the translation of clinical trial findings into individual 
patient needs remains a daunting challenge. Cognitive impair-
ment also plays a role in occupational and social functioning. 
Recent data indicate that, in the case of the atypical antip-
sychotic amisulpride, these properties can be translated into 
a better quality of life, and enhanced social functioning and 
reintegration into society.
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